Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders
LYON, France --(BUSINESS WIRE)--Jul. 12, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into
View HTML
Toggle Summary ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017 . Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about
View HTML
Toggle Summary ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017 . Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about
View HTML
Toggle Summary ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL
LYON, France --(BUSINESS WIRE)--Apr. 4, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the launch of an
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Sep 9 - Sep 10, 2019

Morgan Stanley Global Healthcare Unplugged, New York

Summary Toggle Sep 17, 2019

Business Update and Financial Highlights for the 2nd quarter and first-half of 2019

Summary Toggle Sep 18, 2019 at 8:30 AM EDT

Erytech Pharma Second Quarter 2019 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top